1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

1558. Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab

Filetype[PDF-830.63 KB]


  • English

  • Details:

    • Alternative Title:
      Open Forum Infect Dis
    • Description:
      Background

      Non-meningococcal and nongonococcal Neisseria spp. are usually commensal and rarely cause invasive disease in humans. Eculizumab, a terminal complement inhibitor, increases susceptibility to meningococcal disease, but data on atypical Neisseria spp. disease in persons receiving eculizumab are lacking. This case series describes postmarketing reports of disease by commensal Neisseria spp. in patients receiving eculizumab.

      Methods

      The FDA Adverse Event Reporting System (FAERS) database and the medical literature were searched for cases of disease by any nonmeningococcal and nongonococcal Neisseria spp. in patients receiving eculizumab. Included cases had a diagnosis of disease by any atypical Neisseria spp. with onset on or before January 31, 2018 and ≥1 dose of eculizumab in the 3 months prior to disease.

      Results

      The search identified seven FAERS cases, including one case also reported in the literature. Patient ages ranged from 4 to 38 years. Five patients had positive blood cultures, of which three had an indwelling catheter for vascular access (n = 2, N. sicca/subflava) or hemodialysis (n = 1, N. cinerea). Two patients with bacteremia had N. cinerea septic shock with possible cholecystitis, and N. mucosa sepsis with concurrent Streptococcus bacteremia after gastroenteritis. The remaining two cases in the series included one with N. sicca bacterial peritonitis associated with a peritoneal dialysis catheter (negative blood cultures, other cultures not specified), and one with a diagnosis of N. flavescens sepsis while neutropenic (specimen source not specified). All seven patients were hospitalized and three had sepsis or septic shock. All cases resolved with antibiotics and supportive care.

      Conclusion

      We identified seven cases of serious disease caused by atypical Neisseria spp. among eculizumab recipients. Since these organisms are typical inhabitants of the oropharynx and urogenital tract and are not skin flora, the source of disease was unclear. Our data suggest that eculizumab may confer increased risk for disease by usually commensal Neisseria spp. Healthcare professionals are encouraged to treat all Neisseria spp. isolated from sterile sites as pathogenic, and not as contaminants, in patients receiving eculizumab.

      Disclosures

      All authors: No reported disclosures.

    • Subjects:
    • Pubmed Central ID:
      PMC6252520
    • Document Type:
    • Collection(s):
    • Main Document Checksum:
    • File Type:

    Supporting Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov